- Home
- EDD vs LCTX Comparison
EDD vs LCTX Comparison
Compare EDD & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDD
- LCTX
- Stock Information
- Founded
- EDD 2007
- LCTX 1990
- Country
- EDD United States
- LCTX United States
- Employees
- EDD N/A
- LCTX N/A
- Industry
- EDD Finance Companies
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDD Finance
- LCTX Health Care
- Exchange
- EDD Nasdaq
- LCTX Nasdaq
- Market Cap
- EDD 329.4M
- LCTX 274.0M
- IPO Year
- EDD N/A
- LCTX N/A
- Fundamental
- Price
- EDD $5.30
- LCTX $1.67
- Analyst Decision
- EDD
- LCTX Strong Buy
- Analyst Count
- EDD 0
- LCTX 4
- Target Price
- EDD N/A
- LCTX $4.25
- AVG Volume (30 Days)
- EDD 254.3K
- LCTX 1.7M
- Earning Date
- EDD 01-01-0001
- LCTX 11-13-2025
- Dividend Yield
- EDD 7.52%
- LCTX N/A
- EPS Growth
- EDD N/A
- LCTX N/A
- EPS
- EDD N/A
- LCTX N/A
- Revenue
- EDD N/A
- LCTX $10,914,000.00
- Revenue This Year
- EDD N/A
- LCTX N/A
- Revenue Next Year
- EDD N/A
- LCTX $176.00
- P/E Ratio
- EDD N/A
- LCTX N/A
- Revenue Growth
- EDD N/A
- LCTX 76.43
- 52 Week Low
- EDD $4.22
- LCTX $0.37
- 52 Week High
- EDD $4.95
- LCTX $1.80
- Technical
- Relative Strength Index (RSI)
- EDD 39.65
- LCTX 64.50
- Support Level
- EDD $5.47
- LCTX $1.66
- Resistance Level
- EDD $5.69
- LCTX $1.80
- Average True Range (ATR)
- EDD 0.08
- LCTX 0.12
- MACD
- EDD -0.04
- LCTX 0.01
- Stochastic Oscillator
- EDD 10.95
- LCTX 72.92
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.